Summary
Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m–2, 5-fluorouracil 500 mg m–2, epidoxorubicin 35 mg m–2, 6S stereoisomer of leucovorin 250 mg m–2 and glutathione 1.5 mg m–2, supported by a daily administration of lenograstim at a dose of 5 μg kg–1. Nineteen patients were men and three were women. Median age was 63 years (range 47–70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott–Huskisson scale of 27.6 ± 23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0–26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott–Huskisson scale of 12.3 ± 18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ahlgren, J. D. (1996). Chemotherapy for pancreatic cancer. Cancer 78: 654–663.
André, T., Lotz, J. P., Bouleuc, C., Azzoust, K., Houry, S., Hannoun, L., See, J., Steso, A., Avenin, D. & Izrael, V. (1996). Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 7: 173–178.
Burris, M. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D. & Von Hoff, D. D. (1997). Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403–2413.
Carmichael, J., Fink, U., Russel, R. C. G., Spittle, M. F., Harris, A. & Spiessl, G. (1995). Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101–105.
Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M. & Catalano, G. (1995). Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13: 26–32.
Cascinu, S., Labianca, R., Alessandroni, P., Marcellini, M., Silva, R. R., Pancera, G., Testa, E., Martignoni, G., Barni, S., Frontini, L., Zaniboni, A., Luporini, G., Cellerino, R. & Catalano, G. (1997). Intensive weekly chemotherapy for advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). J Clin Oncol 5: 3313–3319.
Casper, E. S. & Kelsen, D. P. (1995). Adenocarcinoma of the pancreas: overview of workup and management. Adv Oncol 11: 17–22.
Cocconi, G., Bella, M., Zironi, S., Algeri, R., Di Costanzo, F., De Lisi, G., Luppi, G., Mazzocchi, B., Rodino’, C., Soldani, M., Gilli, G. & Finardi, C. (1994). Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12: 2687–2693.
Evans, T. R. J., Lofts, F. J., Mansi, J. L., Gless, J. P., Dalgleish, A. G. & Knight, M. J. (1996). A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73: 1620–1624.
Glimelius, B., Hoffman, K., Sjoden, P. O., Jacobsson, G., Sellstrom, H., Enander, L. K., Linne, T. & Svensson, C. (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593–600.
Kelly, D. M. & Benjamin, I. S. (1995). Pancreatic cancer. Ann Oncol 6: 19–28.
Lionetto, R., Pugliese, V., Bruzzi, P. & Rosso, R. (1995). No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 31A: 882–887.
Moore, M. (1996). Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 78: 633–638.
Miller, A. B., Hoodgstraten, B., Staquet, M. & Winkler, A. (1981). Reporting results of cancer treatment. Cancer 47: 207–214.
Oster, M. W., Gray, R., Panasci, L. & Perry, M. C. (1986). Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, and mitomycin-c (FAM) with 5-fluorouracil, streptozotocin and mitomycin-c (FSM). Cancer 57: 29–33.
Palmer, K. R., Kerr, M., Knowles, G., Cull, A., Carter, D. C. & Leonard, R. C. (1994). Chemotherapy prolongs survival in inoperable pancreatic cancer. Br J Surg 81: 882–885.
Rothenberg, M. L., Abruzzese, J. L., Moore, M. J., Robertson, J. M. & Wanebo, H. J. (1996). A rationale for expanding the end-points for clinical trials in advanced pancreatic carcinoma. Cancer 78: 627–632.
Schnall, S. & Macdonald, J. S. (1996). Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220–228.
Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1–10.
Taylor, I. (1993). Should further studies of chemotherapy be carried out in pancreatic cancer?. Eur J Cancer 29A: 1076–1078.
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlsy, M., Hill, A., Oates, J., Nicolson, M., Hickish, T., O’Brien, M., Iveson, T., Watson, M., Underhill, C., Wardley, A. & Meehan, M. (1997). Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophago-gastric cancer. J Clin Oncol 15: 261–267.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cascinu, S., Frontini, L., Comella, G. et al. Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 79, 491–494 (1999). https://doi.org/10.1038/sj.bjc.6690076
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690076